been diagnosed with immunoglobulin A-λ MM, after presenting with anaemia, hypercalcaemia, acute renal insufficiency and a compression fracture of the T12 vertebra. Her initial symptoms included pain related to the long bones and back. She went into complete remission after being treated with bortezomib, dexamethasone and high-dose melphalan followed by an autologous stem cell transplantation in 2009. Posttransplant, she remained in complete remission and was prescribed maintenance thalidomide therapy.
At referral, the patient was not in any pain and a comprehensive dental examination indicated a good oral status with multiple heavily restored teeth. No evidence of infection or dental pathology was noted. The numbness affected the left side of the lower lip, chin and gingivae of the 32 nd to 36 th teeth. An orthopantomogram and a computed tomography scan showed no evidence of dental or maxillofacial pathology. Based on the clinical presentation, examination and the patient's medical status, the possibility of a relapse of MM was strongly suspected. An urgent magnetic resonance imaging (MRI) examination of the mandible showed an enhancing soft tissue mass in the medial aspect of the left mandibular ramus extending to the bone marrow through the mandibular canal and a soft tissue enhancement near the left mental nerve at the opening of the mental foramen [ Figure 1 ].
A bone marrow aspiration revealed the presence of over 24% plasma cells. A biopsy of the oral cavity lesion showed sheets of plasma cells with plasmablastic morphology and a cellular submucosal infiltrate of the neoplastic plasma cells. The cells were positive for cluster of differentiation (CD) 138 and negative for CD20, CD79a and Epstein-Barr virus, thus excluding a diagnosis of plasmablastic lymphoma. The aggressive nature of the proliferation was supported by the presence of frequent mitosis and a Ki67 proliferation index of >90% [ Figure 2 ]. In combination, these findings confirmed the diagnosis of a relapse of MM both in the bone marrow as well as at extramedullary sites, as indicated by the numbness of the left mental nerve and the soft tissue mass in the left retromolar area. Both the morphological and immunophenotypical features of the oral lesion and bone marrow aspirate histopathology specimens indicated that the relapse was a more aggressive form of the disease.
Over the course of the following weeks, the retromolar mass continued to enlarge and became erythematous and ulcerated [ Figure 3 ]. The patient received lenalidomide and dexamethasone but showed no response to treatment. She was subsequently prescribed a bortezomib-based regimen. However, her condition continued to worsen and she developed multiple infections and extramedullary lesions in the shoulder and lungs. The patient died eight months after the diagnosis of a relapse of MM. decreases the adhesion of plasma cells, resulting in the dissemination of plasma cells away from their original environment and into extramedullary sites. 5 In the current case, the plasma cells showed aggressive behaviour and diffuse neoplastic infiltration into the oral mucosa via histopathology. These cellular features, along with a loss of the CD138 marker, although this was not seen in the present case, generally result in a high-grade malignancy that responds poorly to treatment. 5, 8, 17 Bladé et al. and Damaj et al. have reported that progression of MM into EMM is seen in 15-20% of patients, with an increased frequency in recent years. 18, 19 Relapsing EMM seems to exhibit aggressive behaviour since it manifests as a progression of the disease, leading to a poor prognosis despite various treatment modalities. 17, 19 In addition, survival following an EMM relapse reportedly varies between 4-30 months. [20] [21] [22] In the current case, the patient responded poorly to treatment, developed new lesions at multiple sites and survived for only eight months following the diagnosis. Similar findings have been noted in previous reports. 18, [20] [21] [22] As such, a high index of suspicion is needed when treating patients with a previous history of MM, even during remission.
Conclusion
Relapse of MM in the oral and maxillofacial region is rare. Dental and maxillofacial surgeons should have a high index of suspicion when treating patients with a previous history of neoplastic disease. Such patients should be evaluated by thorough clinical and radiographic examinations to determine the cause of any new symptoms developing, even if they are currently in remission.
Discussion
MM is an uncommon haematological malignancy of the plasma cells which accounts for approximately 10% of all haematological malignancies. 1, 8, 9 It is diagnosed following the proliferation of clonal plasma cells in the bone marrow or an extramedullary lesion (i.e. plasmacytoma), the presence of a monoclonal protein or light chain and end-organ damage, indicated by hypercalcaemia, renal insufficiency, anaemia and bony lesions. 2, 10 The incidence of MM occurring in the maxillofacial region as either a primary manifestation or relapse is low, with few reported cases. 4, [11] [12] [13] Usually, MM appears via imaging as radiolucency in the jaw and the patient may also complain of pain, swelling and mobile teeth. 3, 13 In the present case, the patient was in complete remission when she presented with lip numbness. Initial assessment and routine imaging failed to identify the cause of this sudden neuropathy; however, an MRI scan revealed an altered soft tissue signal with a mass in relation to the inferior alveolar and mental nerves. Similar reported cases of head and neck neuropathies have been observed in patients presenting with primary or secondary EMM. 8, 9, [14] [15] [16] Histopathology of relapsed MM usually reveals numerous immature plasmablastic cells with pleomorphic cellular features indicating its progression and aggressiveness. 8 Recent advances in therapy-for instance, the introduction of thalidomide and lenalidomide as treatments for MM-may contribute to increases in the incidence of EMM. 6, 8 These drugs have been shown to have antiangiogenic and immunomodulatory effects that alter the production of interleukin-6 and tumour necrosis factor-α; this in turn 
